Hot sauces recalled across 10 states
(NewsNation)—A hot sauce recall has been issued across 10 states due to mislabeling, which could have led to unintended sulfites in products.
T.W. Garner Food Company issued the recall for its 'Texas Pete Habanero Buffalo Sauce' after an internal inspection found some contained its siracha sauce, which has sulfites.
A recall was also issued for some of its 'Texas Pete Sweet CHAbanero Sauce ' because some of the labels did not include the ingredient aged peppers.
Consumers can limit their exposure to forever chemicals: Author
The full list of potentially affected items can be found on the Food and Drug Administration's website.
The products were distributed between Feb. 5 and March 26 and sold in retail stores in California, Colorado, Connecticut, Illinois, Massachusetts, North Carolina, New Jersey, Ohio, Virginia and Vermont.
Consumers should dispose of the product or return it to the place of purchase for a refund.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients taking Keytruda can reduce the risk of head and neck cancer recurrence, progression, or death by 30% compared to current treatments. Keytruda is Merck's best-selling drug, generating more than $7 billion in revenue in the first (MRK) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda. The Food and Drug Administration (FDA) has approved Keytruda's use for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express the protein PD-L1. The study's overall principal investigator, Dr. Ravindra Uppaluri, said the approval "represents a potentially significant shift in how we manage this disease." Dr. Uppaluri added Keytruda "has been shown to reduce the risk of recurrence, progression, or death by 30%, compared with standard of care adjuvant chemoradiotherapy or radiotherapy alone." Merck noted that it's estimated that in 2025, there will be approximately 72,680 new cases of head and neck cancer diagnosed, and more than 16,680 deaths from the disease. Keytruda is the company's best-selling drug, with first-quarter revenue of $7.2 billion, making up nearly half of its total sales. Entering Friday trading, shares of Merck were down about 18% year-to-date. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Epoch Times
5 hours ago
- Epoch Times
FDA Approves Moderna's RSV Vaccine for Some Younger Adults, Company Says
Federal regulators approved Moderna's vaccine against Respiratory Syncytial Virus (RSV) for some adults as young as 18, the company said on June 12. The Food and Drug Administration (FDA) expanded approval of the shot to people aged 18 to 59 who face an increased risk from RSV, a virus that typically causes cold-like symptoms, Moderna
Yahoo
14 hours ago
- Yahoo
Ozempic's potential to kill desire for alcohol focus of study
(NewsNation) — Could the most popular weight loss drug double as a treatment for alcoholism? People using Ozempic say they are losing their desire to drink. It's anecdotal evidence right now, but this would be a game-changer for those who are trying to break free from addiction. Drugs like Ozempic and Wegovy are used to treat Type 2 diabetes and obesity. The medicine mimics the behaviors of the natural hormone GLP-1, which controls appetite and regulates blood sugar. Lawsuit alleges Ozempic, Wegovy cause bowel obstruction, stomach paralysis An unintended consequence appears to be that people on the drugs are turning to the bottle less. They say their urge to drink has dramatically decreased. A new clinical trial will study people of normal weight who are dependent on alcohol, notes Pat Aussem with the Partnership to End Addiction. Over five months, participants will get either Ozempic or a placebo, she said. Dr. James Besante, chief medical officer at Sante Fe Recovery Center in New Mexico, agrees the study is exciting, but he cautions it's too early to tell whether the weight-loss drug will be effective for alcoholics. 'These treatments are still considered experimental for addiction,' he told 'Elizabeth Vargas Reports' on Thursday. 'And they're not covered by insurance when they're used for this purpose. And that's really important. It makes them inaccessible for many of the patients I see.' He said there are already proven medications in the marketplace that are covered by insurance. If Ozempic proves to be effective, Besante said, it would effectively become another tool in the medical toolbelt. 'This is a really complex disease that affects different people differently,' he said. 'Rarely is there a magic pill or one medication that's going to solve this person's issue.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
